ImmuCell Corporation (ICCC)

ImmuCell Corp.'s stock has been impacted by several events in the past six months. Strong Q1 2026 sales, driven by Tri-Shield® First Defense®, led to a positive market reaction. Kathy Turner was appointed to the Board of Directors. The company announced full year 2025 financial results, reporting increased product sales and a narrowed net loss. Preliminary sales results for Q4 and full year 2025 were provided, showing a slight decline in Q4 sales but an increase for the full year. A strategic shift from Re-Tain® to focus on First Defense® occurred after an FDA Incomplete Letter. Leadership changes included Olivier te Boekhorst becoming President and CEO, and Timothy C. Fiori being appointed to the Board. The company also announced Q3 2025 financial results.

Demand for ImmuCell Corp.'s products, particularly Tri-Shield® First Defense®, exhibits seasonality, with the peak selling season occurring from November through February. This is driven by the cow-calf segment seeking broad scours protection during this time.

ImmuCell Corp. is an animal health biologics company focused on developing, manufacturing, and commercializing products to enhance the health and performance of neonatal dairy and beef calves. Their primary product line is First Defense®, which provides Immediate Immunity™ to newborn calves and includes products like First Defense®, Tri-Shield® First Defense®, and Dual-Force® First Defense®. The company also offers the California Mastitis Test. ImmuCell shifted its focus to the First Defense® line after receiving an FDA Incomplete Letter for Re-Tain®.

ImmuCell Corp. develops, manufactures, and sells its products in the United States and internationally. Recent growth has been concentrated in the U.S. domestic market, as evidenced by a 35.7% increase in domestic sales in Q1 2026, while international sales declined by 30.2%.

ImmuCell's brand reputation has been shaped by its strategic focus and product performance. The FDA Incomplete Letter for Re-Tain® led to a shift in focus to the First Defense® line. Strong Q1 2026 sales, driven by Tri-Shield® First Defense®, have highlighted the success of its core offerings. The company's emphasis on scientifically-proven products that improve calf health remains a cornerstone of its brand identity.

ImmuCell Corp. is owned by a mix of institutional investors, individual insiders, and retail investors. Institutional investors hold approximately 13.47% to 14.15% of the stock, with major holders including Vanguard Group Inc and Renaissance Technologies Llc. Insiders own approximately 21.30% of the company, with notable individual owners including Norman H. Pessin and Jonathan E. Rothschild. Retail investors hold approximately 64.55% of the stock.